News and Trends 23 Nov 2022 Immune cells in ALS patients can predict the course of the disease By measuring immune cells in the cerebrospinal fluid when diagnosing ALS, it is possible to predict how fast the disease may progress. This according to a study from Karolinska Institutet in Sweden, which has been published in Nature Communications. ALS is a rare, but fatal, disease that affects the nerve cells and leads to paralysis […] November 23, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 23 Nov 2022 Chiesi marks start of Biotech Center of Excellence for the future of medicine in Parma An impressive crowd gathered at Chiesi Pharmaceutical Group yesterday (November 21) to mark the much-anticipated start of work at its Biotech Center of Excellence, bringing the future of medicine to Parma. Guests, which included Vice Minister of Business and Made in Italy, Valentino Valentini, joined to celebrate the start of the work on the building, […] November 23, 2022 - 5 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2022 Agreement boosts mRNA manufacturing in Singapore RVAC Medicines Pte. Ltd., a messenger RNA (mRNA) technology platform company, and the Agency for Science, Technology and Research (A*STAR) have signed a research collaboration agreement to jointly study and develop solutions to build mRNA manufacturing and analytics capabilities in Singapore. RVAC and A*STAR will set up a joint laboratory based at A*STAR’s Bioprocessing Technology […] November 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2022 FMRP – the protein behind immunotherapy resistance Immunotherapy is a cutting-edge approach to treating cancer by turning the patient’s own immune system against their tumor. Despite success rates, immunotherapy has time and again met with a stubborn obstacle: tumor cells often evade the “radar” of immune cells seeking to destroy them. This in turn leads to treatment resistance, which in many cases […] November 21, 2022 - 6 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 18 Nov 2022 New discovery gives hope in fight against metastatic cancer Cancer that splits and develops in new organs around the body becomes significantly more difficult to fight. Researchers at Chalmers University of Technology, Sweden, have shown that these metastatic cancers, which spread from the original, adapt their metabolism to the tissue in which they grow. The discovery represents a breakthrough for the understanding of metastatic […] November 18, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2022 Ascletis announces IND approval for treatment of advanced solid tumors Ascletis Pharma has announced the approval of the investigational new drug (IND) application by China National Medical Products Administration (NMPA). The approval is for an in-house developed oral PD-L1 small molecule inhibitor prodrug, ASC61, for the treatment of advanced solid tumors. The ASC61 phase 1 dose escalation study is ongoing in the U.S. IND approval […] November 17, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 17 Nov 2022 New mitochondria study could pave way for disease treatments Mitochondria, the ‘powerhouses of the cell,’ are important cellular structures that are vital for their role of generating energy. They constantly fuse together and split apart. They contain a small amount of genetic information, mitochondrial DNA (mtDNA). The mtDNA, organized into dot-like structures called nucleoids, also moves around inside the mitochondria. The method of distribution […] November 17, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
More News! 16 Nov 2022 Mineralys has positive topline results from trial evaluating treatment of hypertension U.S.-based Mineralys Therapeutics, Inc., announced today (November 16) topline results from its phase 2 Target-HTN trial in individuals with uncontrolled and resistant hypertension. MLS-101, a highly selective investigational aldosterone synthase inhibitor, at doses of 50 mg and 100 mg once daily, met its primary endpoint with statistically significant and clinically meaningful reduction in systolic blood […] November 16, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 16 Nov 2022 Foodtech company, Wilk, creates first cultured milk fat, cell-based yogurt Israeli company, Wilk, has today (November 16) announced the successful development of the world’s first yogurt developed with cell-cultured milk fat. The company is a developer of cell-cultured human and animal milk and milk components and this hybrid product has been validated by external laboratories, which Wilk says confirms it meets the necessary chemical and […] November 16, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 16 Nov 2022 Bio-Rad introduces pioneer antibody discovery platform for therapeutic development Bio-Rad Laboratories Inc. yesterday (November 15) announced the launch of its Pioneer Platform, a new antibody discovery service specifically designed to develop biologic candidates. The Pioneer Platform features a phage display library engineered to include more than 200 billion unique sequences and capable of identifying high-affinity antibody candidates using Bio-Rad’s newly developed SpyDisplay selection technology. […] November 16, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 16 Nov 2022 Ascletis’ monkeypox tablet receives IND approval from the FDA A drug to treat monkeypox from Ascletis Pharma has had its investigational new drug (IND) application approved by the U.S Food and Drug Administration (FDA). The FDA made its decision based on the available data, which was 800 mg ASC10 taken twice a day, and Ascletis can now go ahead with a phase 1b clinical […] November 16, 2022 - 3 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 16 Nov 2022 Enzymes could be key to understanding ‘origin of DNA errors’ Enzymes, critical to controlling how cells replicate in the human body, could be the very ingredient that encourages DNA to spontaneously mutate – causing potentially permanent genetic errors, according to new research from the University of Surrey in the U.K. Using quantum chemical calculations, researchers from Surrey’s Quantum Biology Doctoral Training Centre have found that […] November 16, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email